Shots:
- Alvotech has signed an exclusive partnership agreement with Advanz Pharma to supply and commercialize AVT06 (2mg, Low dose) and AVT29 (8mg, High dose), biosimilars of Eylea
- As per the agreement, Alvotech will develop & supply the biosimilars and receive an upfront plus subsequent development & commercialization milestones. Advanz Pharma will handle registration & commercialization, with exclusive rights in EU (semi-exclusive in Germany & France)
- AVT06/AVT29 is a VEGF targeting recombinant fusion protein. The equivalence of AVT06 vs Eylea in patients with neovascular (wet) AMD was demonstrated in the study assessing its efficacy, safety and immunogenicity
Ref: Advanz Pharma | Image: Alvotech & Advanz Pharma| Press Release
Related News:- The EC Approves Biogen’s Tofidence (Biosimilar, Roactemra) for Treating Arthritis and COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
